Home / Resources / Looking for biopharma coverage in China? Start here.
eBOOK | MAR 11, 2026

Looking for biopharma coverage in China? Start here.

Are you looking to expand your understanding of China’s rapidly evolving biopharma landscape? Our comprehensive eBook of key articles offers in-depth coverage, strategic insights, and actionable guidance to help you stay ahead in one of the world’s most dynamic markets.

Contents:

  • The Rise of China Biopharma – Five Themes In 2025
  • The Rise In China Deals: How International Biopharma Is Turning To China For Innovation
  • Chinese Firms Launched Fewer Global Phase III Programs With US Sites In 2025
  • China Eyes First-In-Class Blockbuster Drugs In Display of ‘Strategic Purpose’
  • Chinese ADC, Cell/Gene Therapy Biotechs Ride Funding Spree
  • China’s Policies Prompt Reflection Among Global Medtechs As Local Players Adapt

Whether you’re seeking investment insights, partnership opportunities, or the latest on drug development and approval processes, this eBook is your starting point. Download now and equip yourself with the knowledge to succeed in China’s biopharma sector.


Citeline may contact you about relevant products, services, and content. To opt out of these communications or to manage what you receive, please visit our Preference Center.

Your information will be used in accordance with our Privacy notice.
5 key reasons Financial Services professionals need to follow this market:
  1. High-Stakes Investments: Pre-revenue biotech firms are listing on the Hong Kong Exchange, drawing global capital.
  2. Rapid, Cost-Effective R&D: Chinese companies outperform Western peers with faster, more flexible, and cheaper clinical trials, speeding up drug market entry.
  3. Global Innovation Hub: China is now a key source of novel drugs for cancer and other diseases, leading in clinical trials and drug discovery.
  4. Rising Licensing & M&A: Global pharma increasingly partners with Chinese biotechs; nearly a third of large licensing deals involve Chinese companies.
  5. Regulatory & Political Risks: Policy shifts and geopolitical issues, like the US Biosecure Act, impact valuations and operational viability for foreign investors.